FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2400-2402 December 6, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Major depressive disorder is now recognized as one of the world's greatest public health problems: it is common, typically follows a relapsing or recurrent course, disrupts the performance of social and vocational roles, and is associated with increased medical morbidity and reduced life expectancy.¹ During the past several decades, antidepressant medications have become the most widely used means to lessen the suffering and impairments associated with this heterogeneous illness.

Newer medications — such as selective serotonin-reuptake inhibitors and serotonin- and norepinephrine-reuptake inhibitors — have improved on the older standard, the tricyclic antidepressants, in terms of side-effect profiles, ease of use, . . . [Full Text of this Article]

Source Information

From the University of Pennsylvania School of Medicine and the Veterans Affairs Medical Center — both in Philadelphia; and the University of Pittsburgh Medical Center, Pittsburgh.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.